Emily R Mackler,Siobhan Norman,Farah Jalloul-Rizk
Emily R Mackler
Incidental discovery of second primary lung tumors in breast cancer patients: an institutional case series [0.03%]
乳腺癌患者的偶然发现的第二原发肺癌：机构病例系列分析
Alexandra Iancu,William Gwin,Shaveta Vinayak et al.
Alexandra Iancu et al.
Background: Guidelines recommend biopsy of first breast cancer recurrence. Our group recently showed that only half of patients in Washington diagnosed with metastatic breast cancer (MBC) between 2008 and 2017 underwent b...
Case Reports
The oncologist. 2026 Apr 10;31(5):oyag083. DOI:10.1093/oncolo/oyag083 2026
Ghulam Rehman Mohyuddin,Tomer Meirson
Ghulam Rehman Mohyuddin
Re-evaluating treatment strategies: A Closer Look at the FOLFOX-nab-Paclitaxel Approach in the Immunotherapy Era for Metastatic Gastric Cancer [0.03%]
重新评估治疗策略：免疫疗法时代转移性胃癌FOLFOX-nab-紫杉醇方案的再审视
Aysegul Merc Cetınkaya,Yusuf Ilhan
Aysegul Merc Cetınkaya
Concurrent Tissue and Circulating Tumor DNA analysis in Renal Cell Carcinoma: Insights from a Multimodal Database [0.03%]
多模式数据库在肾细胞癌中的并行组织和循环肿瘤DNA分析：启示
Chinmay T Jani,Elizabeth Tran,Ellen Jaeger et al.
Chinmay T Jani et al.
Introduction: Circulating tumor DNA (ctDNA) sequencing complements tissue-based next-generation sequencing (NGS), offering noninvasive and serial testing. We explore the mutational landscape of renal cell carcinoma (RCC) ...
Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis [0.03%]
美国FDA批准的癌症治疗药物的关键研究：一项系统综述和荟萃分析
Ronald Chow,James H B Im,Camilla Zimmermann et al.
Ronald Chow et al.
Background: This study aimed to examine the number of FDA-approved cancer pharmacotherapies and analyse pivotal study characteristics over time, including sample sizes. ...
Meta-Analysis
The oncologist. 2026 Apr 10;31(5):oyag125. DOI:10.1093/oncolo/oyag125 2026
Time dependent outcomes modeling in a real-world analysis of the molecular tumor board at University Cancer Center Hamburg (2016-2022) [0.03%]
汉堡大学癌症中心分子肿瘤委员会真实世界分析的时变结果建模（2016-2022）
Janna-Lisa Velthaus-Rusik,Jan Frederic Weller,Melisa Hoshaber et al.
Janna-Lisa Velthaus-Rusik et al.
Introduction: Molecular tumor boards (MTBs) integrate clinical, pathological, and molecular data to prioritize therapy options. Because MTB-guided treatment starts at varying time points after MTB discussion, vulnerabilit...
Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E-mutant rectal cancer with bowel obstruction [0.03%]
胃和直肠给药的encorafenib联合靶向化疗用于BRAF V600E突变型伴肠道梗阻的局部晚期直肠癌患者
Maximilian Alexander Funk,Volker Heinemann,Veit Bücklein et al.
Maximilian Alexander Funk et al.
The activating BRAF mutation V600E occurs in 8%-12% of metastatic colorectal cancers (mCRC) and is associated with peritoneal carcinomatosis (PC) and poor prognosis. Targeted inhibition with the oral BRAF inhibitor encorafenib, combined wit...
Case Reports
The oncologist. 2026 Apr 10;31(5):oyag103. DOI:10.1093/oncolo/oyag103 2026
MyCODE: a prospective evaluation of lay-language molecular tumor board protocols in precision oncology [0.03%]
我的CODE：精准肿瘤学中非专业语言分子肿瘤委员会协议的前瞻性评价
Ina Pretzell,Anke Fleischhauer,Ilektra Mavroeidi et al.
Ina Pretzell et al.
Background: Molecular Tumor Boards (MTBs) are a pillar of precision oncology, integrating results of extended molecular profiling into clinical care. Yet, their protocols are typically incomprehensible for patients. Syste...
Building HOPE: Operationalizing Hybrid Decentralized Oncology Clinical Trials with Community Providers Beyond Traditional Healthcare System Networks [0.03%]
建立HOPE：在传统医疗系统网络之外与社区提供商合作进行混合去中心化肿瘤临床试验的操作化
J Kaitlin Morrison,Leila Valanejad Kiefer,Allison Camp et al.
J Kaitlin Morrison et al.
Background: Cancer clinical trials are essential to high-quality oncology care, yet regulatory and logistical barriers have concentrated trial activity at academic medical centers (AMCs), limiting access for rural and und...